Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994–2007
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Purpose To assess changes in Medicare payments for neovascular age-related macular degeneration (AMD) since introduction of anti-vascular endothelial growth factor (VEGF) therapies. Design Retrospective, longitudinal cohort study Methods Using the Medicare 5% sample, beneficiaries with new diagnoses of neovascular AMD in 1994 (N=2,497), 2000 (N=3,927), and 2006 (N=6,041) were identified using International Classification of Diseases (ICD-9-CM). The total first year health and eye care costs were calculated for each beneficiary. Propensity score matching was used to match individuals in the 2000 and 2006 cohorts with the 1994 cohort on age, gender, race, Charlson Comorbidity Index, and low vision/blindness. Results The number of beneficiaries newly diagnosed with neovascular AMD more than doubled between the 1994 and 2006 cohorts. Overall yearly Part B payments per beneficiary increased significantly from $3,567 for the 1994 to $5,991 for the 2006 cohort (p<0.01) in constant 2008 dollars. Payments for eye care alone doubled from $1,504 for the 1994 cohort to $3,263 for the 2006 cohort (p<0.01). Most of the increase in payments for eye care in 2006 reflected payments for anti-VEGF injections, which were $1,609 over 1 year. Mean annual numbers of visits and imaging studies also increased significantly between the 1994 and 2006 cohort. Results were similar in the matched sample. Conclusions The introduction of anti-VEGF intravitreal injections has offered remarkable clinical benefits for patients with neovascular AMD, but these benefits have come at the cost of an increased financial burden of providing care for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Monitoring Visual Status: Why Patients Do or Do Not Comply with Practice Guidelines
Sloan, F. A., Brown, D. S., Carlisle, E. S., Picone, G. A., & Lee, P. P. (2004) · Health Services Research · doi:10.1111/j.1475-6773.2004.00297.x · Cited by 90
Self-citation
Cited by
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
Digital technology, tele-medicine and artificial intelligence in ophthalmology: A global perspective
Li, J.-P. O., Liu, H., Ting, D. S. J., Jeon, S., Chan, R. V. P., Kim, J. E., Sim, D. A., Thomas, P. B. M., Lin, H., Chen, Y., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100900 · Cited by 626
Age-Related Macular Degeneration: Genetics and Biology Coming Together
Fritsche, L. G., Fariss, R. N., Stambolian, D., Abecasis, G. R., Curcio, C. A., & Swaroop, A. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090413-025610 · Cited by 534
Zanzottera, E. C., Messinger, J. D., Ach, T., Smith, R. T., Freund, K. B., & Curcio, C. A. (2015) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-16431 · Cited by 164
Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
Finger, R. P., Wickremasinghe, S. S., Baird, P. N., & Guymer, R. H. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.03.009 · Cited by 144
Metadata
- Authors
- Day, S., Acquah, K., Lee, P. P., Mruthyunjaya, P., & Sloan, F. A.
- Venue
- American Journal of Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 152
- Issue
- 6
- Pages
- 1014-1020
- ISSN
- 0002-9394 (ISSN-L)
- OpenAlex
- W2047657288
- Cited by
- 72
- References
- 5
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994–2007. https://app.cochat.ai/papers/10.1016/j.ajo.2011.05.008
- The paper
- Day, S., Acquah, K., Lee, P. P., Mruthyunjaya, P., & Sloan, F. A. (2011). Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994–2007. American Journal of Ophthalmology. https://doi.org/10.1016/j.ajo.2011.05.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.